Histogen Inc. (CPH.F)

0.7290 0.0000 (0.00%) As of 07:23PM CEST. Market open.

Histogen Inc.

10655 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
858 526 3100
https://www.histogen.com

Sector(s): 
Industry: 
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Susan A. Knudson	President, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary	612.4k	N/A	1964

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.

Corporate Governance

Histogen Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.